Genascence Corporation announced that it expects to receive funding from Pacira BioSciences, Inc., DeepWork Capital, University of Florida Research Foundation, Incorporated
May 09, 2022
Share
Genascence Corporation announced that it will receive its series A round of funding on May 10, 2022.
On the same date, the company has received $10,500,000 in its first tranche. The transaction was led by new investor, Pacira BioSciences, Inc. and includes participation from new investors, DeepWork Capital and University of Florida Research Foundation, Incorporated, and existing investor Polymerase Capital. As part of the round, Jackson Streeter of DeepWork Capital has joined the company's board of directors.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Genascence Corporation announced that it expects to receive funding from Pacira BioSciences, Inc., DeepWork Capital, University of Florida Research Foundation, Incorporated
PACIRA BIOSCIENCES, INC. 
